In this context, an unconventional mAb (Enoblituzumab/MGA271), which can operate antibody-dependent cell-mediated cytotoxicity (ADCC), was tested against B7-H3 in phase-I clinical trials on different cancers [122, 140, 141]. Here, CD276 is linked to cancer.